Alpha-Lipoic Acid: The Antioxidant for Nerve Health

← Back to articles

Alpha-lipoic acid (ALA) is a small sulfur-containing molecule. It works as a cofactor in the energy-making reactions of mitochondria and as an antioxidant that operates in both the watery and fatty parts of the cell — an unusual feature. The body makes a little on its own. Supplemental ALA at 300–600 mg/day has the most clinical evidence for diabetic peripheral neuropathy. In Germany, prescription ALA (Thioctacid) has been used as a standard neuropathy treatment for decades.

Diabetic Neuropathy: The Core Evidence

The ALADIN (Alpha-Lipoic Acid in Diabetic Neuropathy) program built the clinical foundation. ALADIN I (Ziegler et al., Diabetologia, 1995) randomized 328 adults with type 2 diabetes and symptomatic neuropathy. Intravenous ALA at 600 mg/day for 3 weeks reduced neuropathic symptoms (pain, burning, tingling, numbness) versus placebo. The SYDNEY 2 trial (Ziegler et al., Diabetes Care, 2006; PMID 17065669) tested oral ALA at 600, 1,200, or 1,800 mg/day for 5 weeks in 181 patients and showed a clinically meaningful drop in symptoms at all three doses, with the best risk-to-benefit ratio at 600 mg/day. A 2012 meta-analysis (Mijnhout et al., International Journal of Endocrinology; PMID 22331979) pooled the available trials and concluded that 600 mg/day IV ALA over 3 weeks produces a significant and clinically relevant reduction in neuropathic pain (Grade A recommendation); the evidence for oral ALA over 3–5 weeks is supportive but less definitive.

R-ALA vs. Racemic ALA

Alpha-lipoic acid comes as two mirror-image forms: R-lipoic acid (the natural, biologically active form) and S-lipoic acid. Most supplements contain a 50/50 racemic mix. R-ALA is the form used in mitochondrial reactions and is roughly 40–50% more bioavailable than racemic ALA in pharmacokinetic studies. Stabilized R-ALA (often as sodium R-lipoate) is sold but costs more. Note that the trials that built the neuropathy evidence used racemic ALA at 600 mg/day. R-ALA may have theoretical advantages, but racemic ALA at trial-validated doses is well supported.

Blood Sugar Effects

ALA boosts glucose uptake by activating AMPK and helping move GLUT4 transporters to the cell surface. Multiple trials have shown small but statistically significant drops in fasting blood glucose and HbA1c at 300–600 mg/day in type 2 diabetes. This is useful, but it also means ALA can interact with insulin and oral diabetes medications and could trigger hypoglycemia. People on metformin, sulfonylureas, or insulin should start at the low end of the dose range and check their blood sugar more often.

Dosing and Practical Tips

The evidence-based oral dose for neuropathy is 600 mg/day on an empty stomach (food cuts ALA absorption by about 30%). Doses above 600 mg/day didn’t add benefit in SYDNEY 2 and increased GI side effects (nausea, stomach upset). ALA can also recycle other antioxidants (vitamins C and E, glutathione, CoQ10) and binds certain metals, giving it a broad biochemical footprint. For people without diabetes, ALA at 300–600 mg/day is sometimes used for general antioxidant support, but the evidence is much weaker outside the neuropathy setting.